Having a biosimilar on formulary makes it more likely the biosimilar will be adopted. Length of time a biosimilar is on market can impact how likely it is to be added to formulary.
The longer a biosimilar is available on the market, the more likely it is to be added to an organization’s formulary; however, length of time on the market does not always translate to increased utilization of the biosimilar, according to a new survey from Vizient Inc. Respondents noted that payer demand is driving biosimilar conversion.
The 2022 Biosimilar Survey included responses from hospital leaders and pharmacy professionals across the country at Vizient member hospitals. The most common reason for adding a biosimilar to the institutional formulary is provider or payer demand (30%), followed by approved review by the Pharmacy and Therapeutics committee (25%) and upon FDA approval (22%). However, 20% said there was no formal procedure.
The most likely time an institution moves to a biosimilar is when starting a new treatment (65%), but 59% said they convert individual patients based on payer demand. Approximately half (48%) also said they convert all patients over time, such as at the start of the next cycle or the renewal of prior authorization, and only 21% said they convert all patients at once, regardless of current therapy.
Half (51%) said payers prefer a specific biosimilar while 36% said payers prefer biosimilars but not a specific product. Only 21% said they consider originator products and biosimilars at parity and 13% prefer the originator product.
Among 9 products reviewed to understand how institutions have implemented automatic therapeutic substitutions, the biosimilar for ranibizumab was the least implemented, with more than 90% of respondents saying it has not been implemented with automatic substitution. Byooviz was approved in September 2021 by the FDA and only launched in the United States on June 2, 2022. A second biosimilar, Cimerli, was approved as an interchangeable biosimilar on August 3 2022, but will not launch until October 2022.
Perhaps unsurprisingly, filgrastim biosimilars are among the products that institutions were most likely to have implemented automatic therapeutic substitutions either in outpatient-only settings, inpatient-only settings, or both. There are 2 filgrastim biosimilars that have been on the market longest among all biosimilars: Granix, which was not approved via the biosimilar pathway, launched November 2013 and Zarxio launched September 2015. Institutions are also very likely to have implemented substitutions for infliximab biosimilars. The first infliximab biosimilar came to market in November 2016.
Looking ahead to 2023, when at least 7 adalimumab biosimilars will hit the market, respondents said payer placement, acquisition price, and interchangeability are the top 3 attributes for selection of an adalimumab biosimilar preferred agent. The Vizient report noted that the high number of adalimumab biosimilars expected to enter the market next year provide “an opportunity for savings for the costly therapeutic.”
Biosimilars added to formularies are more likely to be used to varying degrees. For instance, while 76% said rituximab biosimilars were added to formulary, only 69% said these biosimilars are utilized. However, when infliximab is on formulary is it highly utilized: 88% said infliximab biosimilars were added to formulary and 85% said these biosimilars are utilized.
“Vizient has long urged the adoption of biosimilars to our member healthcare organizations to compete with their branded biologic counterparts as they are just as safe and effective,” Steven Lucio, senior principal, pharmacy solutions, for Vizient, said in a statement. “The introduction of additional biosimilars signals a real savings opportunity for healthcare organizations and their patients.”
The survey was conducted between March 30 and April 28, 2022, and included 124 responses.
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Disease-Modifying Antirheumatic Drugs Linked to Decreased Risk for Autoimmune Thyroid Disease
November 28th 2023A nationwide cohort study linked biologic disease-modifying antirheumatic drugs with decreased risks for the onset of autoimmune thyroid disease in patients with rheumatoid arthritis.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Network Meta-Analysis Validates the Use of Methotrexate in RA Compared With Other Treatments
November 24th 2023A network meta-analysis confirmed the efficacy of methotrexate for patients with rheumatoid arthritis (RA) and validated it as the primary reference conventional synthetic disease-modifying antirheumatic drug for treatment in this population.
Read More